Amplify Weight Loss Drug & Treatment ETF
THNR
6 hedge funds and large institutions have $1.22M invested in Amplify Weight Loss Drug & Treatment ETF in 2026 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
50% more funds holding
Funds holding: 4 → 6 (+2)
19% more capital inflows, than outflows
Capital inflows: $534K | Capital outflows: $450K
5.73% less ownership
Funds ownership: 26.8% → 21.07% (-5.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTS Securities
Miami,
Florida
|
+$421K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$110K |
| 3 |
Root Financial Partners
Encinitas,
California
|
+$1.94K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$523 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$450K |
THNR Hedge Fund Activity: Q3 2026 in Review
6 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Amplify Weight Loss Drug & Treatment ETF (THNR) for Q3 2026, worth a combined $1.22M — up 4.1% from $1.17M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new THNR positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was GTS Securities, opening a new position worth an estimated $421K. The largest seller was Jane Street, exiting entirely with an estimated $450K sold.
- 6 institutional investors held Amplify Weight Loss Drug & Treatment ETF (THNR) as of Q3 2026, up from 4 in Q2 2026.
- Funds reported $1.22M of Amplify Weight Loss Drug & Treatment ETF stock for Q3 2026, up 4.1% quarter-over-quarter.
- 3 funds opened new Amplify Weight Loss Drug & Treatment ETF positions in Q3 2026 and 1 closed out, a net change of +2 holders.
- The largest Amplify Weight Loss Drug & Treatment ETF buyer in Q3 2026 was GTS Securities, an estimated $421K added.
- The largest Amplify Weight Loss Drug & Treatment ETF seller in Q3 2026 was Jane Street, an estimated $450K sold.
Based on aggregated 13F filings for Q3 2026.